Hologic to Webcast Presentations at Upcoming Investor Conferences

Hologic to Webcast Presentations at Upcoming Investor Conferences

May 13, 2025 | Last Trade: US$65.51 2.25 -3.32

MARLBOROUGH, Mass. / May 13, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

The 2025 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 20 at 9:30 a.m. Eastern Time (ET) in New York.
William Blair’s 45^th Annual Growth Stock Conference in Chicago on Wednesday, June 4 at 4 p.m. Central Time
The Jefferies Global Healthcare Conference 2025 in New York on Thursday, June 5 at 11:05 a.m. ET

Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following each event.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Stock Quote

Last Trade:	US$65.51
Daily Change:	-2.25 -3.32
Daily Volume:	2,081,561
Market Cap:	US$14.570B

October 02, 2025 Hologic Receives FDA Clearance and CE Mark for Automated Molecular Tests to Detect Common Causes of Infectious Gastroenteritis September 26, 2025 New Data on Hologic’s AI-Powered Mammography Technology to Be Presented at EUSOBI September 03, 2025 Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference July 30, 2025 Hologic Announces Financial Results for Third Quarter of Fiscal 2025 May 22, 2025 Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients LOAD MORE NEWS

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE